Skip to main content
Top
Published in: Journal of General Internal Medicine 11/2013

01-11-2013 | Clinical Practice: Clinical Vignettes

Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome

Authors: Stephanie A. C. Halvorson, MD, Erin Gilbert, MD, R. Samuel Hopkins, MD, Helen Liu, MD, Charles Lopez, MD, PhD, Michael Chu, MD, Marie Martin, BA, Brett Sheppard, MD

Published in: Journal of General Internal Medicine | Issue 11/2013

Login to get access

Abstract

Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the “glucagonoma syndrome.” A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe a patient with NME and other features of the glucagonoma syndrome. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Surgical and medical treatment options are reviewed. When detected early, a glucagonoma is surgically curable. It is therefore imperative that clinicians recognize the glucagonoma syndrome in order to make an accurate diagnosis and refer for treatment.
Literature
1.
go back to reference Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011;36(1):35–43.PubMedCrossRef Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011;36(1):35–43.PubMedCrossRef
2.
go back to reference Yao J, Eisner M, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492–500.PubMedCrossRef Yao J, Eisner M, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492–500.PubMedCrossRef
3.
go back to reference Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome – cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011;74(5):593–8.CrossRef Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome – cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011;74(5):593–8.CrossRef
4.
go back to reference Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S69–72.PubMedCrossRef Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S69–72.PubMedCrossRef
5.
go back to reference Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24(3):330.PubMedCrossRef Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24(3):330.PubMedCrossRef
6.
go back to reference Wermers R, Fatourechi V, Wynne A, Kvols L, Lloyd R. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63.PubMedCrossRef Wermers R, Fatourechi V, Wynne A, Kvols L, Lloyd R. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63.PubMedCrossRef
7.
go back to reference Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2(3):347–61.PubMedCrossRef Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2(3):347–61.PubMedCrossRef
8.
go back to reference Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol. 2002;57(6):827–31.CrossRef Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol. 2002;57(6):827–31.CrossRef
9.
go back to reference Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321(5):306–20.PubMedCrossRef Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321(5):306–20.PubMedCrossRef
10.
go back to reference Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol. 1998;38(5, Supplement):866–73.PubMedCrossRef Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol. 1998;38(5, Supplement):866–73.PubMedCrossRef
11.
go back to reference van Beek AP, de Haas ERM, van Vloten WA, Lips CJM, Roijers JFM, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.PubMedCrossRef van Beek AP, de Haas ERM, van Vloten WA, Lips CJM, Roijers JFM, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.PubMedCrossRef
12.
go back to reference Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995;80(8):2273–8.PubMedCrossRef Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995;80(8):2273–8.PubMedCrossRef
13.
go back to reference Lobo I, Carvalho A, Amaral C, Machado S, Carvalho R. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol. 2010;49(1):24–9.PubMedCrossRef Lobo I, Carvalho A, Amaral C, Machado S, Carvalho R. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol. 2010;49(1):24–9.PubMedCrossRef
14.
go back to reference Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. Medscape General Medicine. September 10, 2004 ed. Volume 6, 2004. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. Medscape General Medicine. September 10, 2004 ed. Volume 6, 2004.
15.
go back to reference Khandekar J, Oyer D, Miller H, Vick N. Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin. Cancer. 1979;44(6):2014–6.PubMedCrossRef Khandekar J, Oyer D, Miller H, Vick N. Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin. Cancer. 1979;44(6):2014–6.PubMedCrossRef
16.
go back to reference McGevna L, McFadden D, Ritvo J, Rabinowitz T. Glucagonoma-associated neuropsychiatric and affective symptoms: diagnostic dilemmas raised by paraneoplastic phenomena. Psychosomatics. 2009;50(5):548–9.PubMed McGevna L, McFadden D, Ritvo J, Rabinowitz T. Glucagonoma-associated neuropsychiatric and affective symptoms: diagnostic dilemmas raised by paraneoplastic phenomena. Psychosomatics. 2009;50(5):548–9.PubMed
17.
go back to reference Holmes A, Kilpatrick C, Proietto J, Green MD. Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma. Am J Med. 1991;91(4):434–6.PubMedCrossRef Holmes A, Kilpatrick C, Proietto J, Green MD. Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma. Am J Med. 1991;91(4):434–6.PubMedCrossRef
18.
go back to reference Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.PubMedCrossRef Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.PubMedCrossRef
19.
go back to reference Akerstrom G, Hellman P. Surgical aspects of neuroendocrine tumours. Eur J Cancer. 2009;45(Suppl 1):237–50.PubMedCrossRef Akerstrom G, Hellman P. Surgical aspects of neuroendocrine tumours. Eur J Cancer. 2009;45(Suppl 1):237–50.PubMedCrossRef
20.
go back to reference Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors. Cancer. 2009;115(4):741–51.PubMedCrossRef Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors. Cancer. 2009;115(4):741–51.PubMedCrossRef
21.
go back to reference FtAF F, Giovannini M, Monges G, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70(5):907–14.CrossRef FtAF F, Giovannini M, Monges G, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70(5):907–14.CrossRef
23.
go back to reference Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res, Clin Endocrinol Metab. 2007;21(1):69–85.CrossRef Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res, Clin Endocrinol Metab. 2007;21(1):69–85.CrossRef
25.
go back to reference Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600.PubMed Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600.PubMed
26.
go back to reference Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.PubMedCrossRef Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.PubMedCrossRef
27.
go back to reference Norton J, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859–66.PubMedCrossRef Norton J, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859–66.PubMedCrossRef
28.
go back to reference Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol. 2010;3:79–86.PubMed Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol. 2010;3:79–86.PubMed
29.
go back to reference Schmidt C, Bloomston M, Shah MH. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene. 2011;30:1497–505.PubMedCrossRef Schmidt C, Bloomston M, Shah MH. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene. 2011;30:1497–505.PubMedCrossRef
30.
go back to reference Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.PubMedCrossRef Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.PubMedCrossRef
Metadata
Title
Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome
Authors
Stephanie A. C. Halvorson, MD
Erin Gilbert, MD
R. Samuel Hopkins, MD
Helen Liu, MD
Charles Lopez, MD, PhD
Michael Chu, MD
Marie Martin, BA
Brett Sheppard, MD
Publication date
01-11-2013
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2490-5

Other articles of this Issue 11/2013

Journal of General Internal Medicine 11/2013 Go to the issue

Healing Arts: Materia Medica

Five Visits

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.